Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.
Basu A, Prabhu VS, Dorr MB, Golan Y, Dubberke ER, Cornely OA, Heimann SM, Pedley A, Xu R, Hanson ME, Marcella S. Basu A, et al. Among authors: dubberke er. Open Forum Infect Dis. 2018 Nov 15;5(11):ofy218. doi: 10.1093/ofid/ofy218. eCollection 2018 Nov. Open Forum Infect Dis. 2018. PMID: 30460321 Free PMC article.
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Wilcox MH, et al. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615. N Engl J Med. 2017. PMID: 28121498 Free article. Clinical Trial.
Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.
Wilcox MH, Rahav G, Dubberke ER, Gabryelski L, Davies K, Berry C, Eves K, Ellison MC, Guris D, Dorr MB. Wilcox MH, et al. Among authors: dubberke er. Open Forum Infect Dis. 2019 Aug 1;6(8):ofz293. doi: 10.1093/ofid/ofz293. Open Forum Infect Dis. 2019. PMID: 31375837 Free PMC article.
Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.
Gonzales-Luna AJ, Skinner AM, Alonso CD, Bouza E, Cornely OA, de Meij TGJ, Drew RJ, Garey KW, Gerding DN, Johnson S, Kahn SA, Kato H, Kelly CP, Kelly CR, Kociolek LK, Kuijper EJ, Louie T, Riley TV, Sandora TJ, Vehreschild MJGT, Wilcox MH, Dubberke ER; EXPAND Cdiff group. Gonzales-Luna AJ, et al. Among authors: dubberke er. Lancet Infect Dis. 2023 Jul;23(7):e259-e265. doi: 10.1016/S1473-3099(23)00047-6. Epub 2023 Apr 14. Lancet Infect Dis. 2023. PMID: 37062301 Review.
209 results